OrthoPediatrics projects $265M-$269M 2026 revenue and reiterates ~$25M adjusted EBITDA as it targets 2026 free cash flow break-even (NASDAQ:KIDS)August 5, 2026
Gilead outlines 2026 base business sales of $29.8B-$30.1B while raising HIV growth outlook to 9%-10% (NASDAQ:GILD)August 5, 2026
Share Facebook Twitter LinkedIn Pinterest Email New technology that extracts the metal from underground brines has been compared to the shale revolution
